Revenue jumps 216% for the quarter to $10.7 million versus the prior year; and up 246% for the six month period to $18.8 million with $2.0 million in positive cash flow from operations
SALT LAKE CITY, Feb. 15, 2019 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, reports financial results for the three and six months ended December 31, 2018 and provides a business update.
Management Commentary
“I’m pleased with our financial performance with revenue for our most recent quarter of nearly $11 million, up more than three-fold from the year-ago period, marking our ninth consecutive quarter of growth,” said Bradley C. Robinson, CEO of Predictive Technology Group. “Our strong revenue performance for the quarter puts Predictive on a run rate exceeding $40 million for fiscal 2019. Additionally, we generated $2 million in positive cash flow from operations for the past six months that supported the further development and commercialization of proprietary genetic-based diagnostics and therapeutics. We completed the quarter with $2.6 million in cash and no long-term debt.
“We filed a Form 10 registration statement in December 2018 and have been fortunate to have numerous industry-leading advisors assist in guiding this process. Predictive is now a fully reporting company, providing investors with heightened transparency of our financials and operations,” he added. “Importantly, this filing is a major step in the process to list our common stock on NASDAQ, which we expect will provide greater visibility and credibility, and expand our reach to a substantially larger market.”
Recent Highlights
Corporate Developments
• Filed a Form 10 registration statement with the SEC. Predictive is now subject to the reporting requirements of the Exchange Act, including the filing of annual reports on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K, among other requirements.
• Announced John E. Sorrentino as Chairman of the Board in addition to his role as Chair of the company’s Scientific Advisory Board. Mr. Sorrentino has more than 35 years of senior management experience in the life sciences industry, including 15 years in leadership positions at Wyeth/Pfizer.
• Appointed Charles Andres, J.D., Ph.D., to its Scientific Advisory Board. Dr. Andres leads the life sciences group at Wilson Sonsini Goodrich & Rosati’s Washington, DC office and has significant expertise in intellectual property, FDA/regulatory, transactions, business and government matters.
• Completed the initial phase of its new laboratory facility featuring an ISO clean room, which meets Good Tissue Practices (GTP) and Good Manufacturing Practices (GMP) requirements for human cell and tissue products. Predictive expects phase two of the laboratory facility to be completed during second calendar quarter of 2019.
Second Quarter Fiscal 2019 Results-Click Here
Revenues from operations (net) for the three months ended December 31, 2018 totaled $10.7 million, compared with $3.4 million for the three months ended December 31, 2017. The increase of $7.3 million was the result of an expansion of our sales force and distribution networks leading to increased sales of our HCT/Ps and regenerative medicine products.
Cost of goods sold (“COGS”) includes expenses associated with acquisition and processing, manufacture (including material and direct labor), property and equipment depreciation, shipping, and other direct expenses relating to our HCT/Ps and regenerative medicine products. Our gross profit for the three months ended December 31, 2018 was $7.6 million compared with $2.5 million for the three months ended December 31, 2017. The increased gross profit resulted from increased sales and efficiencies introduced into our manufacturing processes.
Sales and marketing expenses for the three months ended December 31, 2018 were $3.4 million, compared with $953,000 for the three months ended December 31, 2017. The increased sales and marketing expenses resulted from corresponding increases in sales and an increase in the number of distributors.
Research and development (R&D) expenses for the three months ended December 31, 2018 were $1.8 million, compared with $37,000 for the three months ended December 31, 2017. The increased research and development expenses resulted from increased focus on product development, streamlining manufacturing methods and additional proprietary research and development work relating to our HCT/Ps and regenerative medicine products. Additionally, we have invested significant amounts in laboratory support in anticipation of the sale of diagnostic products.
General and Administrative (G&A) expenses for the three months ended December 31, 2018 were $2.5 million compared with $1.1 million for the three months ended December 31, 2017. The changes in general and administrative expenses resulted from increased management headcount in fiscal 2018, and stock options and warrants issued for consulting services relating to all business entities in fiscal 2017.
Amortization and depreciation expenses for the three months ended December 31, 2018 were $2.0 million, compared with $850,000 for the three months ended December 31, 2017. The reason for the increase in amortization and depreciation expenses relate primarily to the expense of costs relating to our acquisitions.
The net loss attributable to controlling interest for the three months ended December 31, 2018 was $2.6 million, or $0.01 per share, versus a net loss attributable to controlling interest for the three months ended December 31, 2018 of $376,000, or $0.00 per share.
Year-to-date Financial Results
Revenue for the first six months of fiscal 2019 was $18.8 million, a 246% increase from $5.4 million reported for the first six months of fiscal 2018. Gross profit margin for first six months of 2019 was 68.4%, an improvement from 67.5% from the prior year period.
Operating expenses for the first six months of fiscal 2019 were $17.0 million versus $9.4 million for the prior year period. The increase in the fiscal 2019 period was due to increases in sales and marketing expenses, R&D expenses, and amortization and depreciation expenses, offset in part by lower G&A expenses. For the six months ended December 31, 2018, sales and marketing expenses were $5.8 million, G&A expenses were $5.1 million, R&D expenses were $2.4 million, and amortization and depreciation expenses was $3.7 million.
The company reported an investment loss of $915,000 for the first six months of 2019. The company did not report an investment loss or gain in the prior year period.
The net loss attributable to controlling interest for the first six months of fiscal 2019 was $5.0 million, or $0.02 per share, versus a net loss attributable to controlling interest for the first six months of fiscal 2018 of $5.5 million, or $0.03 per share.
The company reported cash and cash equivalents of $2.6 million as of December 31, 2018 compared with $1.2 million as of June 30, 2018.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com andPredictivebiotech.com.
Financial can be viewed at THE US SEC EDGAR Site per below:
https://www.sec.gov/Archives/edgar/data/1382943/000109181819000029/pred02142019form10q.htm
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Predictive Technology Group Reports Second Quarter Fiscal 2019 Financial
/in Predictive Technology Group, Press Releases /by Yes InternationalRevenue jumps 216% for the quarter to $10.7 million versus the prior year; and up 246% for the six month period to $18.8 million with $2.0 million in positive cash flow from operations
SALT LAKE CITY, Feb. 15, 2019 — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, reports financial results for the three and six months ended December 31, 2018 and provides a business update.
Management Commentary
“I’m pleased with our financial performance with revenue for our most recent quarter of nearly $11 million, up more than three-fold from the year-ago period, marking our ninth consecutive quarter of growth,” said Bradley C. Robinson, CEO of Predictive Technology Group. “Our strong revenue performance for the quarter puts Predictive on a run rate exceeding $40 million for fiscal 2019. Additionally, we generated $2 million in positive cash flow from operations for the past six months that supported the further development and commercialization of proprietary genetic-based diagnostics and therapeutics. We completed the quarter with $2.6 million in cash and no long-term debt.
“We filed a Form 10 registration statement in December 2018 and have been fortunate to have numerous industry-leading advisors assist in guiding this process. Predictive is now a fully reporting company, providing investors with heightened transparency of our financials and operations,” he added. “Importantly, this filing is a major step in the process to list our common stock on NASDAQ, which we expect will provide greater visibility and credibility, and expand our reach to a substantially larger market.”
Recent Highlights
Corporate Developments
• Filed a Form 10 registration statement with the SEC. Predictive is now subject to the reporting requirements of the Exchange Act, including the filing of annual reports on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K, among other requirements.
• Announced John E. Sorrentino as Chairman of the Board in addition to his role as Chair of the company’s Scientific Advisory Board. Mr. Sorrentino has more than 35 years of senior management experience in the life sciences industry, including 15 years in leadership positions at Wyeth/Pfizer.
• Appointed Charles Andres, J.D., Ph.D., to its Scientific Advisory Board. Dr. Andres leads the life sciences group at Wilson Sonsini Goodrich & Rosati’s Washington, DC office and has significant expertise in intellectual property, FDA/regulatory, transactions, business and government matters.
• Completed the initial phase of its new laboratory facility featuring an ISO clean room, which meets Good Tissue Practices (GTP) and Good Manufacturing Practices (GMP) requirements for human cell and tissue products. Predictive expects phase two of the laboratory facility to be completed during second calendar quarter of 2019.
Second Quarter Fiscal 2019 Results-Click Here
Revenues from operations (net) for the three months ended December 31, 2018 totaled $10.7 million, compared with $3.4 million for the three months ended December 31, 2017. The increase of $7.3 million was the result of an expansion of our sales force and distribution networks leading to increased sales of our HCT/Ps and regenerative medicine products.
Cost of goods sold (“COGS”) includes expenses associated with acquisition and processing, manufacture (including material and direct labor), property and equipment depreciation, shipping, and other direct expenses relating to our HCT/Ps and regenerative medicine products. Our gross profit for the three months ended December 31, 2018 was $7.6 million compared with $2.5 million for the three months ended December 31, 2017. The increased gross profit resulted from increased sales and efficiencies introduced into our manufacturing processes.
Sales and marketing expenses for the three months ended December 31, 2018 were $3.4 million, compared with $953,000 for the three months ended December 31, 2017. The increased sales and marketing expenses resulted from corresponding increases in sales and an increase in the number of distributors.
Research and development (R&D) expenses for the three months ended December 31, 2018 were $1.8 million, compared with $37,000 for the three months ended December 31, 2017. The increased research and development expenses resulted from increased focus on product development, streamlining manufacturing methods and additional proprietary research and development work relating to our HCT/Ps and regenerative medicine products. Additionally, we have invested significant amounts in laboratory support in anticipation of the sale of diagnostic products.
General and Administrative (G&A) expenses for the three months ended December 31, 2018 were $2.5 million compared with $1.1 million for the three months ended December 31, 2017. The changes in general and administrative expenses resulted from increased management headcount in fiscal 2018, and stock options and warrants issued for consulting services relating to all business entities in fiscal 2017.
Amortization and depreciation expenses for the three months ended December 31, 2018 were $2.0 million, compared with $850,000 for the three months ended December 31, 2017. The reason for the increase in amortization and depreciation expenses relate primarily to the expense of costs relating to our acquisitions.
The net loss attributable to controlling interest for the three months ended December 31, 2018 was $2.6 million, or $0.01 per share, versus a net loss attributable to controlling interest for the three months ended December 31, 2018 of $376,000, or $0.00 per share.
Year-to-date Financial Results
Revenue for the first six months of fiscal 2019 was $18.8 million, a 246% increase from $5.4 million reported for the first six months of fiscal 2018. Gross profit margin for first six months of 2019 was 68.4%, an improvement from 67.5% from the prior year period.
Operating expenses for the first six months of fiscal 2019 were $17.0 million versus $9.4 million for the prior year period. The increase in the fiscal 2019 period was due to increases in sales and marketing expenses, R&D expenses, and amortization and depreciation expenses, offset in part by lower G&A expenses. For the six months ended December 31, 2018, sales and marketing expenses were $5.8 million, G&A expenses were $5.1 million, R&D expenses were $2.4 million, and amortization and depreciation expenses was $3.7 million.
The company reported an investment loss of $915,000 for the first six months of 2019. The company did not report an investment loss or gain in the prior year period.
The net loss attributable to controlling interest for the first six months of fiscal 2019 was $5.0 million, or $0.02 per share, versus a net loss attributable to controlling interest for the first six months of fiscal 2018 of $5.5 million, or $0.03 per share.
The company reported cash and cash equivalents of $2.6 million as of December 31, 2018 compared with $1.2 million as of June 30, 2018.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com andPredictivebiotech.com.
Financial can be viewed at THE US SEC EDGAR Site per below:
https://www.sec.gov/Archives/edgar/data/1382943/000109181819000029/pred02142019form10q.htm
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Covalent Collective Appoints New CFO and COO
/in Covalent Collective, Inc., Press Releases /by Yes InternationalColorado Springs, Colorado, Jan. 30, 2019 (GLOBE NEWSWIRE) — Covalent Collective, Inc. (“Covalent Collective” or the “Company”), a burgeoning network of vertically integrated cannabis businesses, announced today that the Company has added two new members to its leadership team with the hiring of Anthony Engel as Chief Financial Officer and Douglas Matthews as Chief Operations Officer. Both Mr. Engel and Mr. Matthews will report directly to Bill Gregorak, CEO of Covalent Collective.
Anthony Engel brings extensive financial leadership experience to Covalent Collective having served as CFO across a range of retail, consumer packaged goods, and agricultural verticals. In his role as CFO, Mr. Engel will be responsible for overseeing Covalent Collective’s financial operations and be responsible for managing liquidity, balance sheet risk and capital market transactions to ensure the Company remains well positioned to capitalize on growth opportunities. Before joining Covalent Collective, Mr. Engel served as CFO at Agrium and managed the expansion of the Company’s retail footprint of its agricultural product lines across nine countries and four continents. In addition to his experience at Agrium, Mr. Engel also previously served as Corporate Accounting Manager at Molson Coors and held a leadership role in the IPO processes for three different companies, was involved in numerous debt and equity financings, and oversaw more than fifty acquisitions including managing the successful sale of a national food retailer (Wild Oats) to a strategic buyer (Whole Foods Market).
“I am pleased to announce the addition of Anthony to our executive team. His impressive background and financial leadership experience managing multiple public companies through the IPO process will prove to be an invaluable asset to the Company as it executes on its growth strategy throughout 2019 and beyond,” commented Mr. Gregorak. “As we continue to expand Covalent Collective’s footprint in the U.S. and abroad, Anthony’s deep understanding of executing financial strategies and his strong international experience will be critical as we look forward to continuing to scale the business and build value for shareholders.”
Douglas Matthews joins Covalent Collective as Chief Operations Officer and will be responsible for developing effective and efficient organizational capabilities at both the Company’s corporate headquarters as well as throughout Covalent Collective’s network of vertically integrated cannabis businesses. With experience in consumer products sales, marketing, production and distribution on global basis, Mr. Matthews brings a combination of both tactical and strategic skills with a focus on organizational performance, strategic alignment, relationship development and profitable operational execution to the organization. Before joining Covalent Collective, Douglas served as President/Founder of The 4E Project Inc., a private corporate redevelopment firm engaged in leading organizations’ assessment, refinement and implementation of strategic business expansion, acquisition/divestiture and market expansion activities. Prior to The 4E Project, Douglas spent 14 years with Case Logic, subsequently acquired by Thule, where he served as President of the Organization Solutions business unit, with prior roles as the Senior VP Sales & Marketing, VP of Custom Products group and lead the expansion of the Company’s Asia/Pacific retail and wholesale operations.
“As our operations continue to grow in size and complexity across a network of businesses, we will rely upon Doug’s creative flexibility and global entrepreneurial experience to ensure financial strength and operational efficiency,” added Mr. Gregorak. “With over three decades of experience leading large geographically dispersed organizations, Doug will play a critical role guiding Covalent Collective towards executing its strategic goals and becoming a leading cannabis company.”
About Covalent Collective:
Covalent Collective, Inc. is a British Columbia, Canada company founded in 2014 and headquartered in Colorado Springs, CO. The Company is building a diverse network of vertically integrated cannabis-centric enterprises that span the entirety of the legal cannabis and hemp industries. With a vision to build the largest grow capacity in the U.S., Covalent Collective’s mission is to create stronger bonds throughout the greater cannabis community through the execution of a strategic acquisition and joint venture strategy that is strategically positioned to support eventual federal legalization in the United States. For more information, please visit https://covalentcannabis.com.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward- looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements with respect to the Company’s operations and growth strategies. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievements could differ materially from those expressed in, or implied by, any forward-looking statements in this press release, and readers should not place undue reliance on any such forward-looking statements since they are not guarantees of future results. The Company does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
For further information contact Rich Kaiser, Investor Relations, 757-306-6090 or rich@yesinternational.com rkaiser@covalentcannabis.com
NORTHSTAR ELECTRONICS, INC. (NEIK) PROVIDES AN INTERIM UPDATE AS ITS SUBSIDIARY ACHIEVES ANOTHER MILESTONE
/in Northstar Electronics, Press Releases /by Yes InternationalVirginia Beach, VA.-January 10, 2019 – Northstar Electronics, Inc. (OTCQB: NEIK) is pleased to provide an update to its shareholders on a key milestone achieved by its subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), on a major acquisition.
As previously reported, NEIK and NSEL have been working closely with a major global Aerospace Company with the objective to acquire the worldwide rights and IP for a high-performance Turbo-Prop industrial aircraft.
Recently, the Aerospace Company presented the main details of this complex transaction to the Canadian government’s Industry, Science and Education Department (ISED), where the plan was met with positive and enthusiastic feedback from the department’s representatives. This confirmation of interest in this transaction, and its eligibility for substantial “Offset” credits under ISED’s Industry Trade and Benefits program, will now expedite the planned transaction through the Aerospace Company’s internal review processes. Completion of the review will clear the path toward the final stages of negotiations with NSEL.
To this end, NEIK is moving forward on its plans to provide financial support for the endeavour, aligning key investors and financial instruments, while NSEL continues its pre-sales efforts and its preparations for a rapid and efficient ramp-up to production, and an expedient rise to profitability.
For more details about Northstar Electronics and its subsidiary, Northstar Sealand Enterprises, Ltd., refer to the Company’s website, www.northstarelectronics.com.
For further information about this news release contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.
About Northstar Electronics, Inc.
Northstar Electronics, Inc. (OTCQB:NEIK), established in the late 1990’s, carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. In the past few years, Northstar has moved towards making and selling its own independent systems, www.northstarelectronics.com.
Safe Harbor Statement: This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.
Doyen Elements International Rebrands to Covalent Collective and Appoints Bill Gregorak as Chief Executive Officer
/in Covalent Collective, Inc. /by Yes InternationalColorado Springs, CO, Jan. 08, 2019– Doyen Elements International, Inc., a burgeoning network of vertically integrated cannabis businesses, announces its rebranding and renaming itself to Covalent Collective, Inc. (“Covalent Collective” or the “Company”). In addition, the Company announced Bill Gregorak as Chief Executive Officer, effective immediately. Prior to being named CEO, Mr. Gregorak served as Chief Financial Officer of Covalent Collective since February 2018. Mr. Gregorak takes over as CEO from Geoffrey Thompson, a co-founder of Covalent Collective, who will continue as leader of merger and acquisitions.
“The cannabis industry is evolving even more rapidly than any of the experts expected, and Covalent Collective’s value proposition differentiates us in a crowded marketplace. Over the coming weeks, months and years, the vision we have will yield tremendous shareholder value, and position us for exponential growth,” said Mr. Thompson. “We are confident that the rebrand and name change to Covalent Collective effectively aligns with our core mission of building out a vertically integrated network of unique cannabis enterprises. It also allows us to capitalize on this rapidly expanding market by providing a means to greatly enhance and accelerate our partners’ growth potential. As we continue to grow Covalent Collective, we will focus our efforts on both organic growth and strategic acquisitions.”
In his role, Mr. Gregorak will direct all business units and strategy for Covalent Collective. Mr. Gregorak will also oversee the execution of the Company’s rebranding and acquisition strategy of plant-touching enterprises that grow, process and sell cannabis products.
“As a seasoned executive, Bill Gregorak brings to bear more than two decades of public company experience. Coupled with his broad background in managing relationships with customers, partners and investors, Bill has the right combination of skills and experience to lead our company and senior management team,” added, Mr. Thompson. “Throughout the search process, Bill’s unique skill set stood out as the best candidate for the CEO position and we are thrilled to have him lead us into our next level of growth and expansion.”
Prior to joining Covalent Collective, Mr. Gregorak served as CFO for publicly traded companies on both the NASDAQ and the OTC markets including Two Rivers Water and Farming, a company that builds and leases greenhouses optimized for marijuana cultivation and also specializes in the development of water resources for municipal, commercial and agricultural usage in Southwest Colorado. Mr. Gregorak also spent nearly 20 years with tech giant Hewlett-Packard in various financial and operational capacities.
“Before taking Covalent Collective to the next level, we needed to develop a more sophisticated brand, one that better reflects our mission,” said Mr. Gregorak. “As we take this next step, our goal is to provide tremendous value to our partners, investors and potential shareholders. In order to achieve this, we are confident that a diversified, innovative collective of vertically integrated cannabis enterprises will allow us to optimize efficiency across the entire cannabis ecosystem.”
About Covalent Collective:
Covalent Collective, Inc. is a British Columbia, Canada company founded in 2014 and headquartered in Colorado Springs, CO. The Company is building a diverse network of vertically integrated cannabis-centric enterprises that span the entirety of the legal cannabis and hemp industries. With a vision to build the largest grow capacity in the U.S., Covalent Collective’s mission is to create stronger bonds throughout the greater cannabis community through the execution of a strategic acquisition and joint venture strategy that is strategically positioned to support eventual federal legalization in the United States. For more information, please visit https://covalentcannabis.com.
Media Contacts:
Nick Opich / Cynthia Salarizadeh
KCSA Strategic Communications
(212) 896-1206 / (856) 425-6160
Investor Relations:
Rich Kaiser
YES INTERNATIONAL
757-306-6090
ir@covalentcollective.co
yes@yesinternational.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward- looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements with respect to the Company’s rebranding and acquisition strategies. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievements could differ materially from those expressed in, or implied by, any forward-looking statements in this press release, and readers should not place undue reliance on any such forward-looking statements since they are not guarantees of future results. The Company does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
NORTHSTAR ELECTRONICS, INC. (NEIK) Expands in its Plans to Become an Original Equipment Manufacturer (OEM); Provides Professional Bios on Business Team
/in Northstar Electronics, Press Releases /by Yes InternationalVirginia Beach, VA- August 15, 2018- Northstar Electronics, Inc. (OTCQB: NEIK) proceeds with its expansion from being an aerospace contract manufacturer to becoming an “Original Equipment Manufacturer” (OEM) with its own products. NEIK made significant headway in the purchase of the worldwide rights to a single engine “Turbo Prop” airplane from a major overseas aerospace company. The Company’s management anticipates making a deal with the owners of the airplane in short-order.
The airplane underwent many new design features which should put it at the forefront in its class. NEIK foresees a large market for the two variants of the airplane, one for “Agriculture Crop Spraying,” the other for “Rapid Response Forest Fire Fighting.” Management also plans to expand into “Cloud Seeding,” a rapidly growing business. While the negotiations continue, management plans to secure pre-sales of the airplane, specifically in areas where a former version of the airplane was highly regarded.
Northstar Sealand Enterprises, Ltd., (NSEL), a subsidiary of NEIK, put together a stellar team of professionals. Below, the Company shares a snapshot of their expertise with shareholders and other interested parties:
Wilson Russell, President and CEO: Dr. Russell, a senior corporate executive, has extensive experience in securing investment and developing business opportunities, including partnerships with Bell Canada, Lockheed Martin, Krupp Atlas Elektronik, and Fluor Daniel.
William J. Alder, Special Advisor: Mr. Alder is the owner of the Sealand Group and brings more than 40 years of aviation experience. As an advisor for NSEL, his contribution and expertise will be highly significant to ensure the success of the challenges ahead for the company.
Jeff Fry, VP, Manager – Operations and Engineering: Mr. Fry is a Professional Engineer with over 20 years managing projects for aviation and defense with companies like Lockheed Martin, L-3 Communications, and the International Space Station (private/NASA partnership).
Stewart Gibson, Manager – Contracts, Supply Chain and Logistics: Mr. Gibson is a Project Management professional, who has managed successful production contracts for Lockheed Martin and L-3 Communications, also served as a QA/CM Manager on a number of international programs.
Robert Patterson, Manager – Marketing and Sales: Mr. Patterson is a former consultant with over 35 years of experience across many diverse aviation-related industries. Mr. Patterson brings to NSEL his 25+ years’ experience providing extensive marketing and sales services to Murphy Aircraft, including international representation.
Piers Van Ziffle, Comptroller: Mr. Van Ziffle is an experienced Comptroller with over 40 years’ experience in finance and accounting with both private and public companies, having been a member of the Canadian Institute of Chartered Accountants from 1977 to 1990, and has practiced accounting as a self-employed sub contractor to many companies to date.
Alberto Jurjo, Director – Business Development: Mr. Jurjo is an Aerospace Engineer with 13+ years’ experience in aviation. Alberto has held senior commercial roles with Airbus and Bombardier, having a clear focus and expertise on the commercial, marketing and business development activities.
Nigel Waterhouse, Consultant – DAR Services: Mr. Waterhouse is an Aeronautical Engineer, with an extensive expertise as a Transport Canada Design Approval Representative. He is also an EASA Compliance Verification and an Aircraft Certification engineer, as well as an ICAO Field Project expert.
Tom Serjeant, Consultant – Sales South Africa: Mr. Serjeant brings 40 years of aviation experience as a pilot and as a business developer, being also a professional in aircraft sales. With his extensive experience in the African region, Mr. Serjeant will ensure the success of NSEL’s expansion into that territory.
Robert Gosse, Consultant – Government Relations: Mr. Gosse is a seasoned executive with over 30 years of management experience in diverse aspects of the aviation industry, in both the public and the private sectors. He brings to NSEL his proven track record of achieving strategic business objectives.
Howard Nash, Consultant – Corporate Relationships: Mr. Nash is a senior executive who brings 30 years of experience and a proven track record in business development and supply chain management. He has secured high value contracts with several divisions of Lockheed Martin, L-3, and others.
With this team, NEIK and its subsidiary, NSEL, believe they have the ingredients to establish themselves as a strong player in the “Turbo Prop” aviation world.
For more details about the stellar team of highly acclaimed professionals at Northstar Electronics and its subsidiary, Northstar Sealand Enterprises, Ltd., read more about the team on the Company’s website, http://www.northstarelectronics.com/team.html.
For further information about this news release contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.
About Northstar Electronics, Inc.
Northstar Electronics, Inc. (OTCQB:NEIK), established in the late 1990’s, carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. In the past few years, Northstar has moved towards making and selling its own independent systems, www.northstarelectronics.com.
Safe Harbor Statement: This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) BECOMES FULLY REPORTING PER US SEC 1934 ACT RULES
/in BioForce NanoSciences Holdings, Inc, Press Releases /by Yes InternationalVirginia Beach, VA- BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH: OTCMARKETS) announces that the US SEC regulators approved the Company’s FORM 10 registration under the 1934 Exchange Act (“Act”).
As of August 1, 2018 the Company is fully transparent and filing reports within the rules/regulations required of the 1934 Act.
The US SEC approval of the Company under the “Act” shows, under federal rules/regulations, that BFNH meets the necessary statutes per financial auditing and disclosures standards. Being a “34 Act” entity allows the Company certain benefits which were not attainable otherwise. As such, brokerage houses, national stock exchanges, and other financial institutions require publicly traded entities to be a “34 Act reporting” issuer for trading and listing requirements. Shareholders who own 144 restricted shares can now register their holdings as “free-trade” after a 6-month holding time verses that of 1-year for non-reporting status.
The Company’s shareholders can be assured that the arduous process and cost of becoming fully-reporting was an important fiduciary responsibility of BFNH’s board and management team.
Management believes in a productive future ahead, and being a fully-reporting entity now allows BFNH to negotiate future acquisitions with reasonable terms. BFNH’s management team continues to aggressively look at a number of unique businesses operations with acquisition intentions.
For further information about this release, contact YES INTERNATIONAL, Investor Relations, 757-306-6090, yes@yesinternational.com and www.yesinternational.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.
Northstar Electronics, Inc.’s (NEIK) Progress Update
/in Northstar Electronics, Press Releases /by Yes InternationalVancouver, British Columbia-March 21, 2018 – Northstar Electronics, Inc. (OTCQB:NEIK) provides an updated report on its subsidiary, Northstar Sealand Enterprises Ltd. (NSEL). NSEL continues to work diligently to acquire a “Definitive Agreement” for the worldwide rights to a “Turbo Prop” single engine industrial airplane from a world leader in the aerospace industry. The primary applications of the airplane are for “Agriculture” and “Rapid Response Forest Fire Fighting (RRFFF),” where the needs for both variants of the airplane are high. Management continues to interact weekly with senior managers in the international aerospace company and its subsidiary.
The Company believes the new design features of the NSEL “Agriculture and Rapid Response Forest Fire Fighting” airplanes will quickly lead to it being a leader in its class.
There is a strong possibility that the large aerospace company will use NSEL’s transaction as an “Offset,” which means that much of NSEL’s acquisition costs, including the “Intellectual Property (IP),” prototype, etc., would be covered by them. The valuation of the “Offset” is currently underway.
Cloud Seeding, using a variation of the RRFFF airplane, is being considered as more and more countries face severe water shortages.
NEIK also see significant potential in the field of Counter Insurgency (COIN), and management is exploring future possibilities in this sector. In particular, NEIK’s intention for the future is to develop a “Surveillance Aircraft,” as the requirements for it are similar to those of its subsidiary NSEL’s commercial versions.
Based on the commercial versions, the Surveillance aircraft would be able to fly very low, away from radar detection. NSEL’s plane would be light (20% less than its main competition) with the same engine and power, and would be able to carry +1,500 kg of equipment. It would be the least expensive airplane to operate and it has excellent performance capabilities. Its landing gear would allow the airplane to land on improvised runways, which is excellent for surveillance in remote areas with no infrastructure.
Management will continue to explore the Surveillance opportunity with the intent of taking action on it, once the “Agriculture and RRFFF” versions are well established in the marketplace.
Once agreements are signed-off with the international aerospace company and its subsidiary for the worldwide rights, the Company has plans to move forward, in marketing the airplanes, establishing additional infrastructure, securing pre-production orders, and expanding MRO capability, among other activities.
For further information about this news release contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.
About Northstar Electronics, Inc.
Northstar Electronics, Inc. (OTCQB:NEIK),established in the late 1990’s, carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts, Northstar has moved towards making and selling its own independent systems – www.northstarelectronics.com.
Safe Harbor Statement:
This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.
Predictive Technology Group, Inc.’s (PRED) Subsidiary Provides a Sponsorship at 4th Annual Perinatal Stem Cell Society Congress
/in Predictive Technology Group, Press Releases /by Yes InternationalSalt Lake City, UT- March 5, 2018- Predictive Biotech, Inc., a wholly owned subsidiary of Predictive Technology Group, Inc. (PRED.OTCPINK) provided a sponsorship at the 4th Annual Perinatal Stem Cell Society Congress, Salt Lake City, UT on March 1-2, 2018.
In 2013, the Perinatal Stem Cell Society, Inc. a non-profit organization was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many diseases and disorders. Perinatal stem cell sources include: amnion, amniotic fluid, cord blood, cord tissue/Wharton’s jelly, as well as placental blood and placental tissue
Dr. Doug Schmid, Chief Science and Lab Officer, at Predictive Biotech, Inc., presented an oral presentation to the society titled: “Wharton’s Jelly: A Perinatal Cytokine Reservoir?”
Dr. Schmid received his Ph.D. in Physiology from the University of Utah School of Medicine in Salt Lake City, Utah. He completed four years of post-doctoral training at the University of Utah Medical School and five years as a Research Associate at the University of Utah Medical School as a cellular biologist. Dr. Schmid has 23 years of experience in primary cell culture, tissue processing and cryogenic storage of cells and tissues. After working at the University of Utah, from 2009 to present, Dr. Schmid has established, implemented, and supervised the operational aspects of several tissue companies, including the recovery, quality control, processing, and distribution of tissue. He is passionate about quality and vitality of physiological products and the vast benefits they deliver.
Predictive Technology Group, Inc. wholly owned subsidiary, Predictive Biotech, Inc. is in the business of developing advancements in human cell and tissue products. Data collected in collaboration with other research institutes and clients are the cornerstone in Predictive Biotech’s product development.
For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com
Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) RETAINS DONOHOE ADVISORY ASSOCIATES LLC, TO ASSIST IN PREPARING TO SEEK A LISTING ON A NATIONAL SECURITIES EXCHANGE
/in Predictive Technology Group, Press Releases /by Yes InternationalSalt Lake City, UT- February 27, 2018- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that it has engaged Donohoe Advisory Associates, LLC (“Donohoe Advisory”) in connection with its efforts to seek a listing for its common shares on a national securities exchange.
Donohoe Advisory was founded by Dave Donohoe in 2004, and since that time the firm has successfully represented hundreds of companies in a wide range of listing proceedings and engagements at both Nasdaq and the NYSE. Each professional member of Donohoe Advisory’s team previously worked for either The Nasdaq Stock Market (“Nasdaq”) or the New York Stock Exchange (the “NYSE”). Prior to forming Donohoe Advisory, Dave Donohoe spent 9+ years with Nasdaq, where he ultimately served as Chief Counsel in the Listing Qualifications Department.
Bradley Robinson, CEO, Predictive Technology Group, Inc. states, “At this juncture in PRED’s corporate growth, PRED believes it is well positioned to pursue a listing on a recognized exchange. Hiring Donohoe Advisory will help to further this effort.”
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED’s subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.
For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.
Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES COMPLETION OF GENOTYPING IN TWO CLINICAL TRIALS OF ARTGUIDE™
/in Predictive Technology Group, Press Releases /by Yes InternationalSalt Lake City, UT — February 20, 2018 — Predictive Technology Group, Inc. (OTC PINK: PRED) announces that Predictive Therapeutics, LLC, its wholly-owned subsidiary, completed a crucial milestone in the development and commercialization of ARTGuide™.
The Company’s scientific team completed the genotyping in two clinical trials of ARTGuide™. As such, Company representatives are providing three scientific presentations at the 65th Annual Meeting of the Society for Reproductive Investigation (SRI) on March 9th and 10th in San Diego, CA.
Predictive Therapeutics, LLC anticipates its launch of a novel test for women experiencing infertility, as a result of endometriosis and other health concerns, called ARTGuide™. The test is expected to change the way Advanced Reproductive Technologies (ART), such as In Vitro Fertilization (IVF), are used to help couples struggling to have a baby. After testing thousands of women as part of the development program, the Company now expects commercial launch of the ARTGuide™ infertility test in the United States during Q3 2018.
Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis and pelvic pain.
PRED and its subsidiaries remain leaders in the use of data analytics for disease identification and subsequent therapeutic intervention through unique biotechnology treatments.
About Endometriosis:
Endometriosis affects more than 10 million women in the United States. Endometriosis occurs when the tissue similar to the lining of the uterus (womb), found in other parts of the body -most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women diagnosed with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery.
About Predictive Technology Group, Inc.:
Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Pelvic Pain, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.
For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com.
Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.